Click here to watch video news release about Botox®, reported by Franklin Feinberg.

DALLAS, Apr 16, 2002/ FW/ --- Allergan, Inc. (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has granted approval to BOTOX® Cosmetic (botulinum toxin type A) for the temporary improvement in the appearance of moderate to severe glabellar lines (brow furrow) in adult men and women 65 or younger.

The approval specifically applies to the vertical lines between the eyebrows. In conjunction with this approval, BOTOX® will be marketed for this use under the name BOTOX® COSMETIC with dosing specific to treat frown lines.

Most brow furrow lines are formed by excessive contraction of the two major muscles in the forehead, the corrugator and procerus muscles. BOTOX® COSMETIC works to relax these muscles by blocking nerve impulses that trigger wrinkle-causing muscle contractions, creating a smoothed and improved appearance between the brow.

Administered in a few tiny injections of purified protein, this minimally invasive treatment is simple and quick and delivers dramatic results with minimal discomfort. Results can be seen within 24-48 hours and the effect lasts up to four months.

In clinical trials of BOTOX® COSMETIC, the most frequently reported adverse events (BOTOX® COSMETIC: N = 405; placebo: N = 132) were headache (13.3% of those treated with BOTOX® COSMETIC versus 17.7% of those treated with placebo), respiratory infection (3.5% vs. 3.8% with placebo), blepharoptosis or temporary eyelid droop (3.2% vs. 0% with placebo), nausea (3.0% vs. 2.3% with placebo) and flu syndrome (2.0% vs. 1.5% with placebo).

Less frequently occurring adverse reactions included pain in the face, erythema (redness) at the injection site and muscle weakness. These events are thought to be associated with the injection and occurred within the first week. BOTOX® Cosmetic should not be used in the presence of infection at the proposed injection sites(s).

Allergan's BOTOX® product is the only one of its type with over 10 years of successful clinical experience in therapeutic conditions. Neurological disorders for which BOTOX® therapy is currently approved in the U.S. include treatment of strabismus (crossed eyes), blepharospasm (uncontrollable blinking) and head position and neck pain associated with cervical dystonia (a movement disorder characterized by involuntary muscle contractions).

BOTOX® therapy is approved in 70 countries for a broad range of conditions, and is currently being investigated in the U.S. for the treatment of many different medical conditions including hyperhidrosis (excessive sweating), post-stroke spasticity, back spasm and headache.

Full prescribing information for both BOTOX® and BOTOX® COSMETIC is available at www.botox.com